NEW HAVEN, CT / ACCESSWIRE / July 11, 2017 / Precipio, Inc. (PRPO) ("Precipio" or "Company") today announced it will visit the Nasdaq MarketSite Broadcast Studio at 4 Times Square in New York City on July 12, 2017 and ring the Opening Bell.
CEO, Ilan Danieli, will perform the honorary bell ringing ceremony from approximately 9:20am - 9:30am ET. Members of the Precipio Executive Leadership Team, certain employees and family members and guests will join in the ceremony.
"We have accomplished a great deal with our recent merger with Transgenomic, our recent agreement with Clearbridge Health to expand our footprint in Asia and our listing on NASDAQ, where we began trading on June 30, 2017. These accomplishments are a testament to the shared vision and strong execution of our team in carrying forward the mission of Precipio becoming a leader addressing the challenges of disease misdiagnosis and bringing our innovative platform solution to physicians and their patients around the world. I wish to thank our shareholders for their continued support and the NASDAQ team for the opportunity to share Precipio with its participants and followers during the Opening Bell Ceremony on July 12, 2017," said Ilan Danieli, CEO of Precipio.
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Certain statements in this press release constitute “forward-looking statements,” within the meaning of federal securities laws, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The known risks, uncertainties and other factors affecting these forward-looking statements are described in Transgenomic's definitive proxy statement filed on May 12, 2017, Transgenomic's prior filings and from time to time in Precipio's subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and Precipio does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Precipio Investor Relations:
SOURCE: Precipio, Inc.